Clinical trial · Interventional
Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab
A Prospective Single Institution Study of Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab
NCT01331616CI-TRIAL-00055442withdrawnEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Does treatment with bevacizumab (Avastin) in combination with prior or current radiotherapy lead to optic neuropathy?
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| Optic Neuropathy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab (Avastin) | Drug | Bevacizumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Bevacizumab (Avastin)
- interventionNames
- Drug: Bevacizumab (Avastin)
Primary outcomes (1)
- measure
- Measurement of Visual Evoked Potentials (optic nerve function and visual processing) and optic nerve function in 10 patients.
- timeFrame
- 1 year
- description
- Does Avastin lead to optic neuropathy in combination w chemo-radiotherapy? Our research will focus on patients prior to them beginning treatment with bevacizumab (Avastin), by undergoing Visual evoked Potentials testing. This will allow testing of the patient's optic nerve function bilaterally. In our study of VEP, we will be measuring optic nerve function, to asses if there has been any damage.
Secondary outcomes (1)
- measure
- Number of patients diagnosed with optic neuropathy following treatment with chemo and radiation in combination with avastin treatment
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Diagnosed w Glioblastoma grade IV, and scheduled to begin chemo radiotherapy with Avastin Exclusion Criteria: * No diagnosis of GBM, not scheduled to begin treatment with avastin in combination with radiotherapy.
References
Publications (0)
Data not yet available
No reference posted for this study.